Relationship of timing of agonist administration in the cycle phase to the ovarian response to gonadotropins in the long down-regulation protocols for assisted reproductive technologies.

[1]  H. Kamiya,et al.  [Human embryo cryopreservation]. , 1997, Human Cell.

[2]  L. Gianaroli,et al.  Prospective randomized study of D-Trp6-LHRH versus buserelin in long desensitization protocols for medically assisted conception cycles. , 1994, Human Reproduction.

[3]  R. Edwards,et al.  Comparative trial between an ultra-short and long protocol of luteinizing hormone-releasing hormone agonist for ovarian stimulation in in-vitro fertilization. , 1993, Human reproduction.

[4]  I. Ben-Shlomo,et al.  The relative success of gonadotropin‐releasing hormone analogue, clomiphene citrate, and gonadotropin in 1,099 cycles of in vitro fertilization , 1993, Fertility and sterility.

[5]  S. Campbell,et al.  The routine use of gonadotropin-releasing hormone agonists for all patients undergoing in vitro fertilization. Is there any medical advantage? A prospective randomized study , 1992 .

[6]  L. Gianaroli,et al.  Dopamine treatment for severe ovarian hyperstimulation syndrome. , 1992, Human reproduction.

[7]  B. S. Verkauf,et al.  Prospective randomized study of human menotropin versus a follicular and a luteal phase gonadotropin-releasing hormone analog-human menotropin stimulation protocols for in vitro fertilization. , 1991, Fertility and sterility.

[8]  V. Serra,et al.  Development of ovarian cysts during gonadotrophin-releasing hormone agonists (GnRHa) administration. , 1991, Human reproduction.

[9]  A. Golan,et al.  Follicle cysts after menstrual versus midluteal administration of gonadotropin-releasing hormone analog in in vitro fertilization. , 1990, Fertility and sterility.

[10]  E. Loumaye.  The control of endogenous secretion of LH by gonadotrophin-releasing hormone agonists during ovarian hyperstimulation for in-vitro fertilization and embryo transfer. , 1990, Human reproduction.

[11]  K. Thomas,et al.  Hormonal changes induced by short-term administration of gonadotropin-releasing hormone agonist during ovarian hyperstimulation for in vitro fertilization and their consequences for embryo development. , 1989, Fertility and sterility.

[12]  G. Goldman,et al.  Ovarian cyst formation: a complication of gonadotropin-releasing hormone agonist therapy. , 1989, Fertility and sterility.

[13]  R. Marrs,et al.  Pregnancy: a risk to initiation of leuprolide acetate during the luteal phase before controlled ovarian hyperstimulation. , 1988, Fertility and sterility.

[14]  F. Helmerhorst,et al.  Ovarian cyst formation during the use of a GnRH analogue in an IVF programme. , 1987, Acta Europaea fertilitatis.

[15]  D. Ziegler,et al.  Suppression of the ovary using a gonadotropin releasing-hormone agonist prior to stimulation for oocyte retrieval. , 1987, Fertility and sterility.

[16]  L. Gianaroli,et al.  The successful use of human amniotic fluid for mouse embryo culture and human in vitro fertilization, embryo culture, and transfer. , 1986, Fertility and sterility.

[17]  R. Fleming,et al.  Induction of multiple follicular growth in normally menstruating women with endogenous gonadotropin suppression. , 1986, Fertility and sterility.

[18]  J. Butler,et al.  Neuroendocrine regulation of the corpus luteum in the human. Evidence for pulsatile progesterone secretion. , 1984, The Journal of clinical investigation.

[19]  A. S. Noble,et al.  Steroidogenic responsiveness of the monkey corpus luteum to exogenous chorionic gonadotropin. , 1983, Endocrinology.

[20]  D. Serr,et al.  The study of induction of ovulation with menotropins: analysis of results of 1897 treatment cycles. , 1978, Fertility and sterility.

[21]  S. Korenman,et al.  The menopausal transition: analysis of LH, FSH, estradiol, and progesterone concentrations during menstrual cycles of older women. , 1976, The Journal of clinical endocrinology and metabolism.

[22]  Whittingham Dg.  Culture of mouse ova. , 1971 .